Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)β’ Click on a phase to view related trials
Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting
- Conditions
- Post COVID-19 Condition (PCC)
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- EmitBio Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT06113679
- Locations
- πΊπΈ
Site 2_WellNow Urgent Care and Research, E. Amherst, New York, United States
πΊπΈSite 1_Helios - Physician Quality Care, Milan, Tennessee, United States
Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
- Conditions
- COVID-19
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- EmitBio Inc.
- Target Recruit Count
- 330
- Registration Number
- NCT05817045
- Locations
- πΊπΈ
322 - Desert Clinical Research/CCT Research, Mesa, Arizona, United States
πΊπΈ347 - Velocity Clinical Research, Phoenix, Arizona, United States
πΊπΈ312 - Smart Cures Clinical Research, Anaheim, California, United States
Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19
- Conditions
- COVID19
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- EmitBio Inc.
- Target Recruit Count
- 216
- Registration Number
- NCT04966013
- Locations
- πΊπΈ
Site 2 - Innovative Research of West Florida, Inc., Clearwater, Florida, United States
πΊπΈSite 1 - APF Research LLC, Miami, Florida, United States
πΊπΈSite 8 - WellNow Urgent Care, Kalamazoo, Michigan, United States
Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19
- Conditions
- COVID19
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- EmitBio Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT04662671
- Locations
- πΊπΈ
Site 2, Miami, Florida, United States
πΊπΈSite 1, College Station, Texas, United States
Acute Safety and Acceptability Study of Experimental Device RD19 for Protection From Human Respiratory Disease Pathogens
- Conditions
- Respiratory Tract Infections
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- EmitBio Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04557826
- Locations
- πΊπΈ
Carolina Phase I, Raleigh, North Carolina, United States